Introgen Wins Decision Against Schering-Plough At European Patent Office
The biopharmaceutical company said it won the decision on its opposition of European Patent 0-390-323 before the European Patent Office.
Introgen said all claims directed to therapeutic applications of the p53 gene, the active component of the company's Advexin molecular therapy, were revoked by the EPO's technical board of appeals.
The patent, entitled Detection of Loss of the Wild-Type p53 Gene,...
To view the full article, register now.